

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/86, 5/16, 7/00, A61K 48/00		A1	(11) International Publication Number: <b>WO 98/17815</b>
			(43) International Publication Date: 30 April 1998 (30.04.98)
(21) International Application Number: PCT/GB97/02857 (22) International Filing Date: 17 October 1997 (17.10.97) (30) Priority Data: 9621680.9           17 October 1996 (17.10.96)   GB 9624457.9           25 November 1996 (25.11.96)   GB (71) Applicant (for all designated States except US): OXFORD BIOMEDICA (UK) LIMITED [GB/GB]; Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): KINGSMAN, Alan, John [GB/GB]; Greystones, Middle Street, Islip, Oxon OX5 2SF (GB). KINGSMAN, Susan, Mary [GB/GB]; Greystones, Middle Street, Islip, Oxon OX5 2SF (GB). KIM, Narry [KR/GB]; Linacre College, St. Cross Road, Oxford OX1 3JA (GB). MITROPHANOUS, Kyriacos [GR/GB]; 85 Warwick Street, Oxford OX4 1SZ (GB). (74) Agent: PRIVETT, Kathryn, Louise; Stevens Hewlett & Perkins, 1 Serjeants' Inn, Fleet Street, London EC4Y 1LL (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: RETROVIRAL VECTORS



## (57) Abstract

Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as *vpr*, *vif*, *tat*, and *nef* in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

### RETROVIRAL VECTORS

This invention relates to retroviral vector production systems and to retroviral vector particles produced by the systems. In particular, it relates to systems and vector particles from which certain retroviral auxiliary  
5 factors are absent. The invention also relates to uses of retroviral vectors, in particular for gene therapy.

Retroviral vectors have been the vehicle of choice for clinical gene transfer because of their efficacy, safety, and stable long-term gene expression. According to the United States National Institutes of Health  
10 RAC report issued in September 1996 (Ross et al., 1996), 76 out of 107 trials reviewed by the NIH were based on vector systems derived from the murine leukaemia virus (MLV).

One major drawback of these vectors is their inability to infect non-proliferating cells such as neurons, macrophages and haematopoietic  
15 stem cells. These cells are important targets for gene therapy.

Human immunodeficiency virus type 1 (HIV-1) belongs to a sub-family within the retroviruses, the lentiviruses and in common with other members of this family HIV can infect quiescent cells. This makes  
lentiviruses attractive vectors for gene therapy.

20 The viral determinants for HIV-1 infection of non-dividing cells are thought to reside in the p17 matrix protein (MA) and *vpr* (Gallay *et al.*, 1996). MA has karyophilic properties conferred by a conserved stretch of basic residues, which constitute a nuclear localization signal (NLS) (Bukrinsky et al., 1993). *Vpr* also contains a distinct NLS (Mahalingam *et al.*,  
25 1995). MA-NLS mutant viruses fail to replicate efficiently in macrophages in the absence of a functional *vpr* gene (Heinzinger *et al.*, 1994). These data have been interpreted to mean that *vpr* as well as MA function as karyophilic determinants of HIV-1. In the absence of *vpr* the transduction efficiency of monocyte-derived macrophages decreases by over 50%, in the presence of  
30 functional MA. (Naldini *et al.*, 1996).

- 2 -

Following work reported in Lever *et al.*, 1989 which showed the sequences required for packaging of HIV-1, there has been much interest in the development of an HIV-1 based gene therapy vector. Transfer of foreign genes into a human T-cell line by a replication defective HIV-1 based vector was demonstrated by Poznanski *et al* (Poznansky *et al.*, 1991). Other groups have designed HIV-1 based vectors that are *tat*-inducible (Buchsacher, Jr. and Panganiban, 1992) or that use heterologous promoters (Shimada *et al.*, 1991). However, the viral titers obtained with these vectors was low (at most  $10^3$  infectious particles per ml), and it was not clear whether the vector system could guarantee the production of helper virus-free vectors. More recently, new efforts to produce helper virus-free vectors have been based on three-plasmid cotransfections (Richardson *et al.*, 1995). HIV vectors can be pseudotyped with Vesicular Stomatitis Virus glycoprotein (VSV-G) and these particles retain infectivity after concentration by ultracentrifugation (Akkina *et al.*, 1996). Pseudotyping with VSV-G confers a broader host range and eliminates the chances of recombination to produce wild type HIV envelope. *In vivo* transduction of non-dividing neuronal cells has been demonstrated with VSV-G pseudotyping of HIV-1 in a three-plasmid cotransfection system (Naldini *et al.*, 1996 and Naldini *et al.*, 1996a).

HIV-1 contains nine genes, three of which: *gag*, *pol* and *env* are found in all retroviruses. These are the structural genes. The other six: *vif*, *vpu*, *vpr*, *nef*, *tat* and *rev* are referred to as auxiliary genes. Other retroviruses have different sets of auxiliary genes in their wild type genomes. Some of the auxiliary genes of other retroviruses are analogous to those of HIV-1, although they may not always have been given the same names in the literature. Analogous auxiliary genes have homology in their nucleotide sequences and perform the same or similar functions. HIV-2 and SIV strains generally contain *env*, *vpr*, *vif*, *tat*, and *nef* genes analogous to those of HIV-1. HIV-2 and some strains of SIV also contain *vpx* which, in some SIV

strains lacking *vpr*, can be considered analogous to *vpr*. Lentiviruses other than HIV-1 also contain auxiliary genes which are not analogous to the HIV-1 auxiliary genes. Retrovirus auxiliary genes are reviewed for example by Tomonaga and Mikami (1996) and by Joag *et al.* in Fields Virology, Vol 2.

5           To date all vector systems based on HIV contain some or all of the HIV auxiliary genes. *Rev* acts as an RNA export protein and *tat* is a major transactivator of the proviral long terminal repeat (LTR). The auxiliary genes play a crucial role in viral replication and pathogenesis. The auxiliary genes have not been fully characterized nor their function defined.

10           However some of the auxiliary genes are thought to be involved in the pathogenesis of HIV-1. *Tat* has been implicated in the development of Kaposi's sarcoma (Barillari *et al.*, 1993; Ensoli *et al.*, 1990). HIV *vpr* has been shown to cause cell arrest and apoptosis and this has been proposed to be the cause of T-Cell dysfunction seen in AIDS patients  
15           (Jowett *et al.*, 1995). Also extracellular Vpr present in peripheral blood has been suggested to contribute to tissue-specific pathologies associated with HIV infection since Vpr induces cell proliferation and differentiation (Levy *et al.*, 1993 and Levy *et al.*, 1995).

20           Since the roles of the auxiliary genes are not clear and they probably play a major role in pathogenesis their removal from HIV-1 vector production systems is desirable, provided that sufficiently high retrovirus vector titer and ability to transduce non-proliferating cells can be retained.

          Naldini *et al.*'s data shows that the presence or absence of *vpu* has no effect on the vector particle titer. That is, a packaging system they  
25           used produced a titer of  $4 \times 10^5$  when pseudotyped with VSV-G and this system was *env* and *vpu* negative. In another system which was only *env* negative they obtained the same titer (Naldini *et al.* 1996 and Naldini *et al.* 1996a). However, as already discussed another system of Naldini *et al.* which was *vpr* negative as well as *vpu* negative gave a transduction  
30           efficiency which was decreased by 50% compared to a *vpr* positive system.

- 4 -

We have now discovered that leaving some or all of the auxiliary genes out of retrovirus vector production systems does not significantly compromise vector particle titers or the ability of the vector particles to transduce non-dividing cells.

5           The invention therefore provides in one aspect a retroviral vector production system for producing lentivirus-based, replication defective vector particles for gene therapy, said vector particles capable of infecting and transducing non-dividing mammalian target cells, which system comprises a set of nucleic acid sequences encoding the components of the  
10       vector, wherein one or more functional genes chosen from the HIV-1 auxiliary genes *vpr*, *vif*, *tat* and *nef* or from the analogous auxiliary genes of other lentiviruses, which auxiliary genes are normally present in the lentivirus on which the vector particles are based, is or are absent from the system. The functional *vpu* gene may also be absent, with the proviso that when the  
15       production system is for an HIV-1 based vector and *vpr* and *vpu* are both absent, so also is one of the other auxiliary genes.

          In another aspect, the invention provides retroviral vector particles produced by a retroviral vector particle production system described herein.

20           In yet another aspect, the invention provides a DNA construct for use in a retroviral vector production system described herein, said DNA construct encoding a packagable RNA vector genome for a retroviral vector particle and operably linked to a promoter, wherein all of the functional retroviral auxiliary genes are absent from the construct, other than *rev* which  
25       is optionally present. The DNA construct may be provided as part of a set of DNA constructs also encoding some or all of the structural components of the vector particles.

          In further aspects, the invention provides the use of retroviral vector particles as described herein, for gene therapy and in the preparation  
30       of a medicament for gene therapy; and a method of performing gene therapy

- 5 -

on a target cell which method comprises infecting and transducing the target cell using a retroviral vector particle as described herein. The invention further provides transduced target cells resulting from these uses and methods. The invention thus provides a gene delivery system for use in  
5 medicine.

The expression "lentivirus-based" means that the vector particles are derived from a lentivirus. The genome of the vector particle comprises components from the lentivirus as a backbone. The vector particle as a whole contains essential vector components compatible with  
10 the RNA genome, including reverse transcription and integration systems. Usually these will include the *gag* and *pol* proteins derived from the lentivirus.

Being derived from a lentivirus, the retroviral vector particles are capable of infecting and transducing non-dividing cells. Thus, the vector  
15 particles are able to deliver a selected gene or genes such as therapeutically active genes, to the genome of a target cell. During the infection process, lentiviruses form a pre-integration complex in the target cell cytoplasm containing integrase, core proteins and proviral DNA. The complex is able to pass across the nuclear membrane of the target cell, by means of signal  
20 sequences in the proteins. Non-lentiviral retroviruses either lack the proteins or have the proteins but without the appropriate signal sequences.

Examples of lentiviruses are HIV-1 and HIV-2, SIV, FIV, BLV, EIAV, CEV and visna virus. Of these, HIV and SIV are presently best understood. However, a non-immunodeficiency virus may be preferred for  
25 use in gene therapy because the immunodeficiency viruses inevitably bring with them safety considerations and prejudices.

The absence of functional auxiliary genes from the retroviral vector production system means that those functional genes will also be absent from retroviral vector particles produced by the system. Also, any  
30 auxiliary proteins that would otherwise be encoded by those genes and



- 6 -

incorporated into the vector particles, will be absent from the vector particles.

In known retroviral vector production systems, the auxiliary genes may be present as part of the vector genome-encoding DNA, or together with the packaging components. The location of an auxiliary gene in a vector  
5 production system depends in part on its relationship with other retroviral components. For example, *vif* is often part of a *gag-pol* packaging cassette in a packaging cell. Thus, to remove a functional auxiliary gene for the purposes of the invention may involve its removal from the packaging components, or from the vector genome, or perhaps both.

10 To remove a functional auxiliary gene may not require removal of the gene in its entirety. Usually removal of part of the gene, or disruption of the gene in some other way will be sufficient. The absence of a functional auxiliary gene is understood herein to mean that the gene is not present in a form in which it is capable of encoding the functional auxiliary protein.

15 In a preferred system according to the invention, functional *vpr* and *tat* genes or analogous genes normally present in the lentivirus on which the vector particles are based are both absent. These two auxiliary genes are associated with characteristics of lentiviruses which are particularly undesirable for a gene therapy vector. However, other than by the proviso  
20 given above, the invention is not limited with regard to the combination of auxiliary genes that are absent. In a system according to the invention for producing HIV-1-based vector particles, any combination of three, or more preferably four, of the genes may be absent in their functional form. Most preferably, all five of the auxiliary genes *vpr*, *vif*, *tat*, *nef*, and *vpu* are absent  
25 in their functional form. Similarly, for systems concerned with other lentiviruses, it is most preferable that all of the auxiliary genes are absent in their functional form (except *rev* which is preferably present unless replaced by a system analogous to the *rev*/RRE system).

In order to ensure efficient export of RNA transcripts of the  
30 vector genome from the nucleus to the cytoplasm, it is preferable to include

- 7 -

functional *rev* and *rev* response element (RRE) sequences in the vector genome, or to include alternative sequences in the genome which perform the same function as the *rev*/RRE system. For example, a functional analogue of the *rev*/RRE system is found in Mason Pfizer monkey virus.

- 5 This is known as CTE and consists of an RRE-type sequence in the genome which is believed to interact with a factor in the infected cell. The cellular factor can be thought of as a *rev* analogue. Thus, CTE may be used as an alternative to the *rev*/RRE system.

- As will be evident, in order to function as a vector the retroviral
- 10 vector particles described herein will need to have a reverse transcription system (compatible reverse transcription and primer binding sites) and an integration system (compatible integrase and integration sites) allowing conversion to the provirus and integration of the double-stranded DNA into the target cell genome. Additionally, the vector genome will need to contain
- 15 a packaging signal. These systems and signals will generally be derived from the lentivirus on which the vector is based. It will be evident that although the vector according to the invention is based on a lentivirus, the elements of the lentivirus incorporated into the vector may be genetically or otherwise altered versions of the elements in the wild type lentivirus.
- 20 Alterations may be achieved by manipulating either the RNA genome or other components of the retroviral vector particle production system. For example, portions of the lentivirus genome not required for the vector can be excluded. Also, the vector production system can employ substitutes e.g. for the lentivirus *env* gene, to give the vector a different target cell range (this is
- 25 known as pseudotyping).

- A retroviral vector particle according to the invention carries one or more selected genes for delivery to a target cell. The selected genes are chosen according to the effect sought to be achieved. For gene therapy purposes there will be at least one therapeutically active gene encoding a
- 30 gene product which is active against the condition it is desired to treat or

- 8 -

prevent. Additionally there may be a selected gene which acts as a marker by encoding a detectable product. Therapeutic genes may encode for example an antisense RNA, a ribozyme, a transdominant negative mutant of a target protein, a toxin, a conditional toxin, an antigen that induces  
5 antibodies or helper T-cells or cytotoxic T-cells, a single chain antibody or a tumour suppressor protein.

Preferably the construction of the vector genome is such that in the DNA provirus, the therapeutic gene or genes is or are under transcriptional control of the 5' LTR but not otherwise operably linked to any  
10 other promoter from the vector. Thus, expression of the gene or genes is in a single transcription unit. Preferably also the 5' LTR is a modified lentivirus LTR for which the promoter function is not *fat*-dependent. This may be achieved by replacing the R and U3 lentivirus promoter functions by alternative promoter functions, which may be derived from another retrovirus  
15 or may be of non-retroviral origin. A strategy for this is described in Cannon *et al* 1996 and in the Examples.

It will be evident that the term "gene" is used loosely here, and includes any nucleic acid coding for the desired polypeptide or RNA. Usually, genes delivered by vectors according to the invention will be  
20 cDNAs.

Retroviral vector particles according to the invention will also be capable of infecting and transducing cells which are slowly-dividing, and which non-lentiviruses such as MLV would not be able to efficiently infect and transduce. Slowly-dividing cells divide once in about every three to four  
25 days. Mammalian non-dividing and slowly-dividing cells include brain cells, stem cells, terminally differentiated macrophages, lung epithelial cells and various other cell types. Also included are certain tumour cells. Although tumours contain rapidly dividing cells, some tumour cells especially those in the centre of the tumour, divide infrequently.

30 The DNA construct encoding the vector genome described

- 9 -

herein is preferably linked to a high efficiency promoter such as the CMV promoter. Other high efficiency promoters are known. This gives rise to a high level of expression of the vector RNA by the retroviral vector production system.

5           Suitable host or producer cells for use in the retroviral vector production system according to the invention are well known in the art. Many retroviruses have already been split into replication defective genomes and packaging components. For those which have not the technology is available for doing so. The producer cell encodes the viral components not  
10           encoded by the vector genome such as the *gag*, *pol* and *env* proteins. The *gag*, *pol* and *env* genes may be introduced into the producer cell and stably integrated into the cell genome to give a packaging cell line. The retroviral vector genome is then introduced into the packaging cell line by transfection or transduction to create a stable cell line that has all of the DNA sequences  
15           required to produce a retroviral vector particle. Another approach is to introduce the different DNA sequences that are required to produce a retroviral vector particle e.g. the *env* coding sequence, the *gag-pol* coding sequence and the defective retroviral genome into the cell simultaneously by transient triple transfection. In a preferred system according to the invention,  
20           both the structural components and the vector genome will all be encoded by DNA stably integrated into a host cell genome.

In the attached figures:

Figure 1 shows a vector production system according to the invention, using a three-plasmid co-transfection of 293T cells;

25           Figure 2 shows HIV-based vector genomes for use in the invention;

Figure 3 shows HIV-1 *gag-pol* gene expression plasmids for use in the invention; and

30           Figure 4 shows transduction efficiencies for vectors according to the invention lacking the five auxiliary factors.

- 10 -

To produce a safe HIV packaging system devoid of all unnecessary genes, we have developed a system which does not contain *vpr*, *nef*, *tat*, *vif* or *vpu* (Figure 1.). The packaging components were placed on three separate plasmids and overlapping sequences were minimised ensuring no recombination and no helper virus production. This HIV vector has been shown to transduce aphidicolin treated non-dividing cells in the absence of *vpr*. Titers were obtained that are similar to the Naldini *et al* titers for systems which contain all the auxiliary genes ( Naldini *et al*. 1996a).

This is the first minimal lentiviral vector system. The fact that high titers are observed with this system shows that the auxiliary genes (except *rev*) are redundant for the production of high titers and for the transduction of non-dividing cells. This is contrary to the assumption made by Naldini *et al* that the reason for the production of high titer virus stocks is due to the incorporation of accessory proteins (such as *nef*) into the viral particle (Naldini *et al* 1996).

The system may have additional advantages for HIV therapy. Replacing the HIV-1 LTR with a different promoter such as a constitutive HCMV promoter permits the use of anti-Tat molecules such as Tat transdominant mutants (Echetebu *et al*, 1994) or TAR decoys (Liszewicz *et al*, 1993) as therapeutic agents as they will not affect vector production.

It will be evident that minimal lentiviral vectors as described herein, lacking all of the wild-type virus auxiliary genes, may also have applications as vaccines.

## EXAMPLES

### Materials and Methods

#### Plasmid Construction

pGP-RRE1 is a pWI3 (Kim *et al.*, 1989) derived *gagpol vif* expression plasmid. The RRE of pWI3 (Accession number: U26942) was inserted by blunt-ending the Sty I/Sty I fragment (7720-8050) into pBluescript

- 11 -

KS+ Sma I cut creating pBSRRE. The Nar I/Eco RI fragment of pWI3 (637-5743) was inserted into pBSRRE cut with Cla I and Eco RI to create pBSGPRRE1. The Xho I/Not I fragment (containing *gagpol* and RRE) was inserted into the expression plasmid pCI-Neo to create pGR-RRE1. To  
5 remove the *vif* coding region, pBSGPRRE1 was cut with Nde I and Sma I, blunt-ended and was relegated to generate pBSGPRRE2. The *gagpol* gene and RRE were inserted into pCI-neo in Xho I and Not I site to make pGP-RRE2.

The construction of pTIN406, pTIN408 and pTIN414 has been  
10 described (Cannon *et al.*, 1996). The 5' LTR of pH3Z and pH4Z contain a CMV promoter at the U3 position and the HIV R and U5 regions. HIVdge was made from HIVgpt (Page *et al.*, 1990) by blunt-ending the Cla I site (829) to create a frameshift mutation. HIVdge was cut with Bgl II and Pst I (473-1414) and inserted into pTIN406. pTIN406 has an LTR structure of  
15 CMV, R (HIV) and U5 (MLV). This created a hybrid LTR containing CMV, and R, U5 from HIV called pBS5'. To provide the plasmid with *rev* and RRE the Eco RI/Xho I fragment (5743-8897) was cut from HIVdge1.2 which is a HIVdge derivative containing a deletion from Nde I to Bgl II (6403-7621) and was inserting into pBS5' to create pBS5'R. The 3' LTR was provided by  
20 inserting the Not I/Xho I fragment of pBS3' into pBS5'R creating pH2. pBS3' was created by a three way ligation of the Xho I/Hind III fragment of pWI3, the Hind III/Kpn I fragment of pTIN408 into pBluescript KS+ (Xho I/Kpn I). A CMV promoter was inserted into the unique Xho I site of pH2 from pSPCMV (Sal I/Xho I) making pH2CMV. pSPCMV was created by inserting pLNCX  
25 (Accession number: M28246) (Pst I/Hind III) into pSP72 (Promega). The  $\beta$ -galactosidase gene was inserted from PTIN414 into pSP72 (Xho I/Sph I) to make pSPlacZ. A Xho I/Sal I digest of pSPlacZ gave the  $\beta$ -galactosidase coding region which was inserted into pH2-CMV to give pH3Z. pH4Z was constructed to create *tat*-deficient vector. The first 50 bp of the *tat*-coding  
30 region was removed by replacing EcoRI (5743)I-SpeI fragment in pH3 with

- 12 -

EcoRI (5881)-SpeI PCR product amplified using PCR primers DELT5 (5'-CGTGAATTCGCCTAAACTGCTTGTACCA-3') and DELT3 (5'-GAACTAATGACCCCGTAATTG-3') to create pH4. The Nsi I/Spe I fragment from pH4 was inserted into pH3Z to generate pH4Z.

5                   A *vpr* expression plasmid was constructed by PCR amplification of the *vpr* coding region from pNL4.3 (Accession number: U26942) using the following primers: 5' primer GCGAATTCGGATCCACCATGGAACAAGCCCCAGAAGAC (5563-5583) and 3' primer GCGAATTCGGATCCTCTAGGATCTACTGGCTCCATT  
10 (5834-5853). This amplicon was cloned into pLIGATOR (R & D Systems). The expression plasmid pCI-*vpr* was made by inserting the Mlu I and Xho I fragment containing the *vpr* coding region into pCI-Neo (Promega).

pAC29.1 was cut by Bam HI to give the VSV-G coding region which was inserted into pSA91 (Bgl II).

15

### Cell Lines

293T (293ts/A1609) (DuBridge *et al.*, 1987) cells were maintained in Dulbecco's modified Eagle's medium (GIBCO), HeLa cells and 208F cells in MEM (GIBCO), all of which containing 10 % (v/v) fetal calf  
20 serum supplemented with antibiotics.

### Production and Assays of Vectors

Retroviral vector stocks were produced according to our previously published protocol (Soneoka *et al.*, 1995). Briefly, human kidney  
25 293T ( $1.5 \times 10^6$ ) cells were plated on 10-cm plates and transiently transfected with 15mg of each plasmid (*gag-pol* and *env* expression plasmids together with a vector plasmid) by calcium phosphate DNA precipitation (Chen and Okayama, 1987). The culture supernatants were harvested 36 hours later, filtered through 0.45 mm and either used  
30 immediately or frozen at  $-70^\circ \text{C}$ . Transduction was carried out by adding

- 13 -

virus onto target cells for 2 hours, in the presence of 8 mg/ml polybrene followed by the addition of fresh media. 5-bromo-4-chloro-3-indolyl  $\beta$ -D-galactoside (X-Gal) was used to measure the expression of  $\beta$ -galactosidase 48 hours later, as previously described (Soneoka et al., 1995). Titers were  
5 obtained by counting the number of lac z (blue foci) forming units per ml (i.f.u./ml). G1/S phase arrested cultures were prepared by adding aphidicolin (5 mg/ml) 24 hours before infection and then daily throughout the experiment.

## 10 Results

### HIV vector production

H3Z (*tat* positive) and H4Z (*tat* negative) are HIV-1 based vectors designed to be produced by three plasmid co-transfection into 293T cells (Figure. 2). For efficient packaging by the HIV cores, the vectors  
15 contain the first 778 bases of *gag* but a frameshift mutation, introduced 40bp from the ATG start codon, prevents the expression of *gag* proteins. RRE was included to boost packaging efficiency and *rev* is expressed from the vector to support the HIV mRNA export. The internal CMV promoter-driven  $\beta$ -galactosidase gene was inserted to serve as a reporter gene. For both the  
20 vector genomes transcription is driven by a CMV promoter which has been used to replace the 5' LTR U3. This makes the vector genome *tat* independent. Two HIV-1 *gagpol* constructs were made (Figure. 3); pGP-RRE1 (*vif* positive) and pGP-RRE2 (*vif* negative). Since the *gagpol* genes have been inserted into pCI-neo which is a CMV driven expression plasmid  
25 *gagpol* expression is *tat* independent. pRV67, the VSV glycoprotein construct was used for the pseudotyping. By placing the different genes on different plasmids the probability of generating replication competent virus by recombination could be minimized.



- 14 -

### Transduction efficiency of the vector

Replication defective retroviral particles were generated by transient co-transfection of human kidney 293T cells with the three plasmids described above and either used immediately or frozen at -70 °C. The  
5 different vector constructs were used to produce virus. It was found that the minimal constructs (H4Z and pGP-RRE2) gave comparable titers to that of the *vif*, *vpr*, *nef* and *tat* positive viruses (Table 1).

When the minimal system was tested on various cell lines the titers differed (Table 2). The vectors yielded titers of  $3.2 \times 10^5$  i.f.u./ml with  
10 polybrene treatment,  $9.1 \times 10^4$  i.f.u./ml without polybrene treatment in 293T cells. Also the same vectors, without polybrene, yielded  $9.6 \times 10^3$  i.f.u./ml and  $8.3 \times 10^3$  i.f.u./ml in HeLa and 208F cells, respectively. These titers are comparable with those obtained by Naldini *et al.*, 1996 (Naldini *et al.*, 1996), which are the highest ones published so far.

15

### Effect of *vpr* on the transduction of aphidicolin-treated cells

To test the effect of *vpr* on non-dividing cell transduction, *vpr* was included in the packaging system by co-transfection of pCI-*vpr* along with pH4Z, pGP-RRE2 and pRV67 plasmids. The transduction efficiencies  
20 of the viral particles generated were assayed on growing and growth-arrested 293T cells and HeLa cells (Figure. 4). MLV-derived packaging and transducing vectors (Soneoka, 1995) served as controls. HeLa cells and 293T cells were growth-arrested at G1/S phase by aphidicolin treatment. The minimal HIV vector H4Z was as efficient at transducing G1/S-arrested  
25 as proliferating HeLa and 293T cells, whereas the MLV-based vector was only 0.002 % as effective.

*Vpr*-deficient H4Z could transduce the growth-arrested cells as efficiently as *vpr*-containing vector, suggesting that HIV-1 MA is sufficient for providing the vector with the ability to transduce non-dividing cells.

30

- 15 -

### Conclusion

We have set up an HIV-1 based vector production system, which does not contain *vpr*, *vpu*, *nef*, *vif* and *tat* based on a three-plasmid co-transfection method. This vector can transduce proliferating cells with a  
5 titer of up to  $3.2 \times 10^5$  i.f.u./ml, which is comparable to other MLV-based vectors and can easily be increased by concentration using ultracentrifugation (data not shown). No helper virus has been detected (data not shown).

This minimal vector has been demonstrated to transduce  
10 growth-arrested HeLa cells and 293T cells as efficiently as *vpr*, *vif*, *nef* and *tat* containing vectors. Therefore it can be concluded that only *rev* is required for the production of high titer HIV based vectors and that these vectors can transduce non-dividing cells.

This is the first report of the construction of a high titer minimal  
15 lentiviral vector that can transduce non-dividing cells. The removal of five out of the six auxiliary genes (except *rev*) and the minimal sequence overlap between the plasmids makes this system the safest one to date for the production of HIV-vectors for gene therapy.

### Figure Legends

**Figure 2.** HIV vector genomes. The numbers indicate the coordinates from HXB2. HCMV promoter (-597 to -1). HIV sequences (455 to 1415; 5743 (H3Z) or 5881 (H4Z) to 6403; 7621 to 8897; 8897 to 9720) from HXB2. HCMV promoter as an internal promoter (900 bp).  
20 Cloning site (XhoI). Backbone; pBluescriptKS+.

**Figure 3.** HIV-1 *gag-pol* gene expression plasmids. HIV-1 *gag-pol* coding region and RRE was cloned into pCI-neo (PROMEGA) at XhoI and NotI site.

- 16 -

**Figure 4.** Transduction of non-dividing cells. Transduction efficiencies of the H4Z vectors were measured by X-gal staining and are shown in Y-axis as I.f.u./ml. G1/S phase arrested cells were prepared by treating the cells with aphidicolin (5 µg/ml).

5

## References

- Akkina, R.K., Walton, R.M., Chen, M.L., Li, Q.X., Planelles, V., and Chen, I.S.** (1996). *J. Virol.* 70, 2581-2585.
- 10 **Barillari, G., Gendelman, R., Gallo, R.C., and Ensoli, B.** (1993). *Proc. Natl. Acad. Sci. U. S. A.* 90, 7941-7945.
- Buchsacher, G.L., Jr. and Panganiban, A.T.** (1992). *J. Virol.* 66, 2731-2739.
- Bukrinsky, M.I., Haggerty, S., Dempsey, M.P., Sharova, N., Adzhubel, A.,**
- 15 **Spitz, L., Lewis, P., Goldfarb, D., Emerman, M., and Stevenson, M.** (1993). *Nature* 365, 666-669.
- Cannon, P.M., Kim, N., Kingsman, S.M., and Kingsman, A.J.** (1996). *J. Virol.* 70, 8234-8240.
- Chen, C. and Okayama, H.** (1987). *Mol. Cell Biol.* 7, 2745-2752.
- 20 **Echetebe, C. O., H. Rhim, C. H. Herrmann and A. P. Rice** (1994), *J. Acquired Immune Defic. Syndrome.* 7, 655-664.
- Ensoli, B., Barillari, G., Salahuddin, S.Z., Gallo, R.C., and Wong Staal, F.** (1990). *Nature* 345, 84-86.
- Gallay, P., Stitt, V., Mundy, C., Oettinger, M., and Trono, D.** (1996). *J. Virol.*
- 25 70, 1027-1032.
- Heinzinger, N.K., Bukinsky, M.I., Haggerty, S.A., Ragland, A.M., Kewalramani, V., Lee, M.A., Gendelman, H.E., Ratner, L., Stevenson, M., and Emerman, M.** (1994). *Proc. Natl. Acad. Sci. U. S. A.* 91, 7311-7315.
- Joag, S.V., Stephens, E.B. and Narayan, O.** in *Fields Virology*, Vol 2, 1970-
- 30 1982 (Lippincott-Raven Publishers).

- 17 -

- Jowett, J.B., Planelles, V., Poon, B., Shah, N.P., Chen, M.L., and Chen, I.S.** (1995). *J. Virol.* 69, 6304-6313.
- Kim, S.Y., Byrn, R., Groopman, J., and Baltimore, D.** (1989). *J. Virol.* 63, 3708-3713.
- 5 **Lever, A., Gottlinger, H., Haseltine, W., and Sodroski, J.** (1989). *J. Virol.* 63, 4085-4087.
- Levy, D. N., L. S. Fernandes, W. V. Williams, and D. B. Weiner** (1993), *Cell*, 72, 541-50.
- Levy, D. N., Y. Refae;, and D. B. Weiner** (1995), *J. Virol.*, 69, 1243-52.
- 10 **Lisziewicz, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reitz and R. C. Gallo** (1993), *Proc. Natl. Acad. Sci, USA*, 90, 8000-4.
- Mahalingam, S., Collman, R.G., Patel, M., Monken, C.E., and Srinivasan, A.** (1995). *Virology* 212, 331-339.
- 15 **Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M., and Trono, D.** (1996). *Science* 272, 263-267.
- Naldini, L., Blomer, U., Gage, F.H., Trono, D., and Verma, I.M.** (1996). *Proc. Natl. Acad. Sci. U. S. A.* 93, 11382-11388.
- Page, K.A., Landau, N.R., and Littman, D.R.** (1990). *J. Virol.* 64, 5270-5276.
- 20 **Poznansky, M., Lever, A., Bergeron, L., Haseltine, W., and Sodroski, J.** (1991). *J. Virol.* 65, 532-536.
- Richardson, J.H., Kaye, J.F., Child, L.A., and Lever, A.M.** (1995). *J. Gen. Virol.* 76, 691-696.
- Ross, G., Erickson, R., Knorr, D., Motulsky, A.G., Parkman, R., Samulski, J.,**
- 25 **Straus, S.E., and Smith, B.R.** (1996). *Hum. Gene Ther.* 7, 1781-1790.
- Shimada, T., Fujii, H., Mitsuya, H., and Nienhuis, A.W.** (1991). *J. Clin. Invest.* 88, 1043-1047.
- Tomonaga, K. and Mikami, T.** (1996). *J. General Virol.* 77, 1611-1621.

- 18 -

**Table 1.** Effects of accessory gene expression on vector titer.

Accessory genes				Plasmids				Titer (l.f.u./ml) <sup>a</sup>
<u>Tat</u>	<u>Vif</u>	<u>Nef</u>	<u>Vpr</u>	<u>Vector</u>	<u>Gagpol</u>	<u>Nef</u>	<u>Vpr</u>	
+	+	-	+	pH3Z	pGP-RRE1		pCI-Vpr	2.2 x 10 <sup>5</sup>
+	+	+	-	pH3Z	pGP-RRE1	pC-Nef		2.5 x 10 <sup>5</sup>
+	+	-	-	pH3Z	pGP-RRE1			4.0 x 10 <sup>5</sup>
+	-	-	-	pH3Z	pGP-RRE2			3.7 x 10 <sup>5</sup>
-	-	-	-	pH4Z	pGP-RRE2			4.6 x 10 <sup>5</sup>

a: Transduction efficiency was measured in 293T cells by counting the  
 5 number of blue colonies following X-gal staining 48 hours after transduction  
 and were indicated as lacZ colony forming unit per ml virus stock (l.f.u./ml).

**Table 2.** Transduction efficiency of the minimal H4Z vector on various cell  
 10 lines.

Cell line		Titer (l.f.u./ml) <sup>a</sup>	
		Without polybrene	With polybrene
293T	Human kidney	9.1 x 10 <sup>4</sup>	3.2 x 10 <sup>5</sup>
HeLa	Human epithelium	9.6 x 10 <sup>3</sup>	N.D.
208f	Rat fibroblast	8.3 x 10 <sup>3</sup>	N.D.

a: Transduction efficiency was measured by counting the number of blue  
 colonies following X-gal staining 48 hours after transduction and were  
 15 indicated as lacZ colony forming unit per ml virus stock (l.f.u./ml).

### CLAIMS

1. A retroviral vector production system for producing lentivirus-based, replication defective vector particles for gene therapy, said vector particles capable of infecting and transducing non-dividing mammalian target cells, which system comprises a set of nucleic acid sequences encoding the components of the vector, wherein one or more functional genes chosen from the HIV-1 auxiliary genes *vpr*, *vif*, *tat* and *nef* or from the analogous auxiliary genes of other lentiviruses, which auxiliary genes are normally present in the lentivirus on which the vector particles are based, is or are absent from the system.
2. The retroviral vector production system according to claim 1 for producing HIV-1-based vector particles, wherein the functional auxiliary gene *vpu* is also absent, with the proviso that when functional *vpu* and *vpr* genes are both absent, so also is one or more of the auxiliary genes chosen from *vif*, *tat* and *nef*.
3. The retroviral vector production system according to claim 1 or claim 2, wherein functional *vpr* and *tat* genes or analogous genes normally present in the lentivirus on which the vector particles are based are both absent from the system.
4. The retroviral vector production system according to any one of claims 1 to 3 for producing HIV-based vector particles, wherein three or four or all five of the functional auxiliary genes *vpr*, *vif*, *tat*, *nef* and *vpu* are absent from the system.
5. The retroviral vector production system according to any one of claims 1 to 4, wherein a nucleic acid sequence encoding the RNA genome of the vector comprises one or more therapeutically active genes.

- 20 -


6. The retroviral vector production system according to any one of claims 1 to 5, wherein the set of nucleic acid sequences encoding the components of the vector includes three DNA constructs which encode the RNA genome of the vector, *gag* and *pol* proteins, and *env* protein or a substitute therefor, respectively.
7. The retroviral vector production system according to any one of claims 1 to 6, wherein a nucleic acid sequence encoding the RNA genome of the vector comprises *rev* and RRE sequences or functional equivalents thereof, to enable export of transcripts of the genome from nucleus to cytoplasm.
8. The retroviral vector production system according to any one of claims 1 to 7, in a host cell.
9. The retroviral vector production system according to any one of claims 1 to 8, wherein all of the functional auxiliary genes normally present in the lentiviruses on which the vector particles are based are absent from the system, other than *rev* which is optionally present.
10. A DNA construct for use in the system according to claim 9, said DNA construct encoding a packagable RNA vector genome and operably linked to a promoter.
11. A DNA construct as claimed in claim 10, wherein the promoter is a non-retroviral, high efficiency promoter.
12. A set of DNA constructs for use in the system according to claim 9, comprising the DNA construct according to claim 10 or claim 11, and a DNA construct encoding *gag* and *pol* proteins.
13. A set of DNA constructs as claimed in claim 12, further comprising a DNA construct encoding *env* protein or a substitute therefor.
14. DNA constructs for use in the system according to claim 9, comprising the DNA constructs according to any one of claims 10 to 14, in one or more expression vectors.

- 21 -

15. A retroviral vector particle produced by the system according to any one of claims 1 to 9.
16. The use of a retroviral vector particle according to claim 15, for gene therapy for infection and transduction of a target cell.
- 5 17. The use of a retroviral vector particle according to claim 15, in the preparation of a medicament for use in gene therapy.
18. A method for performing gene therapy on a target cell, which method comprises infecting and transducing the target cell with a retroviral vector according to claim 15.
- 10 19. Target cells resulting from the use or method according to any one of claims 16 to 18.



Fig.1.








Fig.4.



## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N5/16 C12N7/00 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 19798 A (DANA FARBER CANCER INST INC) 26 December 1991 see page 6, paragraph 3	1-8, 10-19
Y	see page 20, paragraph 1; figures 2,3 ---	9
X	EP 0 611 822 A (WISCONSIN ALUMNI RES FOUND) 24 August 1994	1-5,8, 10,14-19
Y	see page 3, line 29 - line 49 see page 10; claims 4,7-9 see page 6, line 45 - line 50 ---	9
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

26 February 1998

Date of mailing of the international search report

17.03.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NALDINI L ET AL: "IN VIVO GENE DELIVERY AND STABLE TRANSDUCTION OF NONDIVIDING CELLS BY A LENTIVIRAL VECTOR" SCIENCE, vol. 272, no. 5259, 12 April 1996, pages 263-267, XP000583652 cited in the application see page 263, left-hand column, paragraph 2 see page 265, middle column ---	1,5-8, 15-19
P,X	WO 97 12622 A (SALK INST FOR BIOLOGICAL STUDI) 10 April 1997 see page 8, line 30 - page 9, line 29; claims 1-3,7 ---	1-19
P,X	ZUFFEREY, R. ET AL.: "Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo." NATURE BIOTECHNOLOGY, vol. 15, 9 September 1997, pages 871-875, XP002056816 see abstract; figure 3; table 1 ---	1-19
A	WO 92 21750 A (US GOVERNMENT) 10 December 1992 see the whole document ---	7
A	WO 95 30755 A (HISAMITSU PHARMACEUTICAL CO ;SHIMADA TAKASHI (JP); AKIYAMA KATSUHI) 16 November 1995 see figure 1 & EP 0 759 471 A see the whole document -----	11

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 97/02857

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 97/02857

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 16 and 18 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9119798 A	26-12-91	CA 2084659 A	21-12-91
		EP 0536234 A	14-04-93
		JP 5508320 T	25-11-93
		US 5665577 A	09-09-97
EP 0611822 A	24-08-94	JP 6261764 A	20-09-94
		US 5554524 A	10-09-96
WO 9712622 A	10-04-97	AU 7168196 A	28-04-97
WO 9221750 A	10-12-92	AU 2007392 A	08-01-93
		CA 2109579 A	10-12-92
		EP 0588914 A	30-03-94
		JP 6510181 T	17-11-94
WO 9530755 A	16-11-95	AU 2419595 A	29-11-95
		EP 0759471 A	26-02-97